Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Celldex Therapeutics, Inc. (CLDX : NSDQ)
 
 • Company Description   
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.

Number of Employees: 134

 
 • Price / Volume Information   
Yesterday's Closing Price: $29.16 Daily Weekly Monthly
20 Day Moving Average: 564,472 shares
Shares Outstanding: 46.75 (millions)
Market Capitalization: $1,363.35 (millions)
Beta: 2.69
52 Week High: $57.20
52 Week Low: $26.26
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -13.83% -2.96%
12 Week -2.80% 6.85%
Year To Date -24.53% -8.55%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
53 FRONTAGE ROAD SUITE 220
-
HAMPTON,NJ 08827
USA
ph: 908-200-7500
fax: 908-454-1911
ir@celldex.com http://www.celldex.com
 
 • General Corporate Information   
Officers
Anthony S. Marucci - President; Chief Executive Officer and Director
Karen L. Shoos - Chairman and Director
Sam Martin - Senior Vice President;Chief Financial Officer and
Keith L. Brownlie - Director
Herbert J. Conrad - Director

Peer Information
Celldex Therapeutics, Inc. (CORR.)
Celldex Therapeutics, Inc. (RSPI)
Celldex Therapeutics, Inc. (CGXP)
Celldex Therapeutics, Inc. (BGEN)
Celldex Therapeutics, Inc. (GTBP)
Celldex Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 15117B202
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 46.75
Most Recent Split Date: 2.00 (0.07:1)
Beta: 2.69
Market Capitalization: $1,363.35 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.43 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.01 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.42
Price/Cash Flow: -
Price / Sales: 329.31
EPS Growth
vs. Year Ago Period: -16.67%
vs. Previous Quarter: -13.95%
Sales Growth
vs. Year Ago Period: -74.60%
vs. Previous Quarter: -47.75%
ROE
03/31/22 - -20.68
12/31/21 - -21.98
09/30/21 - -22.71
ROA
03/31/22 - -19.37
12/31/21 - -20.40
09/30/21 - -20.74
Current Ratio
03/31/22 - 26.83
12/31/21 - 24.86
09/30/21 - 30.09
Quick Ratio
03/31/22 - -
12/31/21 - 24.86
09/30/21 - 30.09
Operating Margin
03/31/22 - -1,793.67
12/31/21 - -1,456.59
09/30/21 - -716.23
Net Margin
03/31/22 - -1,860.46
12/31/21 - -1,516.04
09/30/21 - -891.70
Pre-Tax Margin
03/31/22 - -1,865.94
12/31/21 - -1,520.92
09/30/21 - -906.08
Book Value
03/31/22 - 8.51
12/31/21 - 8.99
09/30/21 - 9.40
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©